Virtual Library
Start Your Search
Runlei Hu
Author of
-
+
P1.14 - Radiotherapy (ID 700)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Radiotherapy
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.14-007 - Mesenchymal Stem Cells Labeled with Fluorescent Magnetic Nanoparticles for Targeted Imaging and Hyperthermia Therapy of Lung Cancer (ID 7524)
09:30 - 09:30 | Presenting Author(s): Runlei Hu
- Abstract
Background:
Lung cancer is the leading cause of cancer-related mortality. It remains a challenge to simultaneously detect and treat early lung cancer in vivo. Herein, we report the use of fluorescent magnetic nanoparticles-labeled mouse mesenchymal stem cells to accomplish targeted imaging and hyperthermia therapy of lung cancer in vivo.
Method:
The silica-coated fluorescent supermagnetic nanoparticles (FMNPs) were prepared and characterized, and then were used to label mouse mesenchymal stem cells（MSCs). The FMNPs-labeled MSCs were injected via tail vein into nude mice bearing non-small cell lung cancer A549 cells, which were followed using small animal imaging system and magnetic resonance imaging system. Thesubcutaneous lung cancer tissues in the nude mice models were subsequently treated in external alternating magnetic field.
Result:
.Results showed that FMNPs -labeled MSCs could target and image in vivo lung cancer cells after being intravenously injected for 7 days, and FMNPs-labeled MSCs could inhibit the growth of in vivo lung cancer through hyperthermia effects. The potential mechanism is discussed.
Conclusion:
FMNPs-labeled MSCs may target in vivo lung cancer cells and have great potential in applications such as targeted imaging and hyperthermia therapy of early lung cancer in the near future.
-
+
P3.16 - Surgery (ID 732)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Surgery
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.16-040 - Intrapleural Perfusion Thermo-Chemotherapy for Pleural Effusion Caused by Lung Carcinoma under VATS (ID 7568)
09:30 - 09:30 | Presenting Author(s): Runlei Hu
- Abstract
Background:
The aim of this study was to assess the effectiveness of Intrapleural Perfusion Thermo-Chemotherapy (IPTC) under video-assisted thoracoscopic surgery (VATS) for malignant pleural effusion (MPE) caused by lung carcinoma.
Method:
In this retrospective study, fifty-four patients with moderate or large amounts of ipsilateral malignant pleural effusion (MPE) secondary to non-small cell lung cancer (NSCLC) underwent pleural biopsy and IPTC under VATS. IPTC was performed by perfusing the pleural cavity with 43.0[o]C saline solution containing cisplatin (200 mg/m[2]) using a devised circuit through mechanical circulation for 60 minutes. Blood pressure, heart rate, oxygen saturation (spo2), and esophageal and rectal temperatures were monitored throughout the surgery. At the end of the perfusion, pleural biopsy was performed again for histological analysis.
Result:
The temperature at the pleural surface was stabilized at 43°C, and pleural effusion was controlled in all patients. KPS scores increased in 89.3% of patients. No patient developed bone marrow suppression reactions with noticeable bleeding after treatment, and no liver and kidney malfunctions were observed. Apoptosis was detected by light and electron microscopy after IPTC. CEA markedly decreased in all patients 1 month after IPTC. The median survival time was 21.7 months, with a one-year survival rate of 74.1%.
Conclusion:
Intrapleural Perfusion Thermo-Chemotherapy under VATS is a new, safe, less invasive and more effective approach for malignant pleural effusion (MPE) caused by lung carcinoma.
